Condition: Advanced Solid Tumor, Adult · ERBB2 Altered Breast Cancer · ERBB2 Gene Amplification · Sponsor: Cogent Biosciences, Inc.
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.
This description comes directly from the study's public registry record.
Cogent Biosciences, Inc · 617-945-5576 · trialinfo@cogentbio.com
Always discuss trial participation with your own doctor first.
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| NYU Langone | New York, New York, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| NEXT Oncology Texas | Austin, Texas, United States | Recruiting |
| START Mountain Region | West Valley City, Utah, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07361562